Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions An OncotypeDX (ODX) recurrence score aims to (a) provide prognosis with respect to 10-year recurrence of breast cancer, and (b) guide the need for adjuvant chemotherapy (ACT) treatment. The evidence base for the use of ODX in women with ER+ HER2- LN- early stage breast cancer (ESBC) to guide ACT treatment decisions includes four recent examples of secondary research (health technology assessments [HTAs] and systematic reviews [SRs]) and four additional primary studies. There is no evidence related specifically to men. Results consistently show about 30% of treatment plans are affected, primarily being lower rates of ACT for patients determined to be at low recurrence risk. For a smaller proportion determined to be at higher risk, ACT is suggested where initial treatment planning did not include ACT. The most uncertainty relates to the intermediate risk category where evidence is unclear; a large 7-country study (TAILORx) is focussing on the treatment of this group with study completion planned for late 2017. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasmss; Gene Expression Profiling Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000796 Date abstract record published 10/07/2014 |